Ironvine Capital Partners LLC Has $38.30 Million Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Ironvine Capital Partners LLC increased its stake in Thermo Fisher Scientific by 5.8%, acquiring an additional 4,188 shares in the first quarter, bringing its total holdings to 76,977 shares valued at approximately $38.3 million.
• CEO Marc N. Casper sold 10,000 shares of Thermo Fisher stock for about $5 million, resulting in a 7.99% decrease in his ownership of the company.
• The company announced a quarterly dividend of $0.43 per share, with a payout date of October 15th, reflecting a 0.4% dividend yield.

Ironvine Capital Partners LLC raised its position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 5.8% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 76,977 shares of the medical research company's stock after purchasing an additional 4,188 shares during the period. Thermo Fisher Scientific comprises approximately 4.2% of Ironvine Capital Partners LLC's portfolio, making the stock its 11th biggest holding. Ironvine Capital Partners LLC's holdings in Thermo Fisher Scientific were worth $38,304,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of the company. Jacobs Levy Equity Management Inc. acquired a new stake in shares of Thermo Fisher Scientific during the first quarter valued at $12,401,000. Gotham Asset Management LLC boosted its stake in shares of Thermo Fisher Scientific by 30.6% during the first quarter. Gotham Asset Management LLC now owns 38,344 shares of the medical research company's stock valued at $19,080,000 after acquiring an additional 8,993 shares during the last quarter. Hancock Whitney Corp boosted its stake in shares of Thermo Fisher Scientific by 1.4% during the first quarter. Hancock Whitney Corp now owns 5,463 shares of the medical research company's stock valued at $2,718,000 after acquiring an additional 77 shares during the last quarter. Edmond DE Rothschild Holding S.A. boosted its stake in shares of Thermo Fisher Scientific by 8.9% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 39,503 shares of the medical research company's stock valued at $19,657,000 after acquiring an additional 3,236 shares during the last quarter. Finally, EdgePoint Investment Group Inc. acquired a new stake in shares of Thermo Fisher Scientific during the first quarter valued at $172,139,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded up $2.71 during midday trading on Friday, reaching $492.20. 1,442,575 shares of the company traded hands, compared to its average volume of 1,612,563. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $627.88. The company has a fifty day moving average price of $460.72 and a 200 day moving average price of $452.29. The firm has a market capitalization of $185.86 billion, a price-to-earnings ratio of 28.47, a price-to-earnings-growth ratio of 2.63 and a beta of 0.75.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company had revenue of $10.86 billion for the quarter, compared to the consensus estimate of $10.68 billion. During the same quarter in the previous year, the business earned $5.37 EPS. The company's quarterly revenue was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. The ex-dividend date is Monday, September 15th. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. Thermo Fisher Scientific's payout ratio is 9.95%.

Insider Activity

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction that occurred on Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the sale, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This represents a 14.24% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Gianluca Pettiti sold 400 shares of the firm's stock in a transaction that occurred on Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This represents a 1.76% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 29,666 shares of company stock valued at $13,982,763. Insiders own 0.33% of the company's stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of analyst reports. Barclays increased their price objective on Thermo Fisher Scientific from $450.00 to $490.00 and gave the company an "equal weight" rating in a research note on Thursday, July 24th. Wall Street Zen lowered Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday. Robert W. Baird raised their price target on Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a research note on Thursday, July 24th. Royal Bank Of Canada set a $561.00 price target on Thermo Fisher Scientific and gave the stock an "outperform" rating in a research note on Tuesday, September 2nd. Finally, UBS Group raised their price target on Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a research note on Thursday, July 24th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $589.38.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.